Atlas Trials

Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years

Clinical trial NCT05406154 · UNKNOWN

Trial details

NCT number
NCT05406154
Sponsor
Peking University Third Hospital
Status
UNKNOWN
Study type
OBSERVATIONAL
Mantle Cell Lymphoma (MCL)
Start date
2020-12-30
Primary completion
2023-12-30
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.